Elan holders OK buyback, vote down three deals (Update)

Shareholders of Irish drugmaker Elan Corp. PLC have potentially ended a takeover bid from Royalty Pharma by voting in favor of an Elan share buyback plan.

The Dublin-based company's shareholders also rejected at a Monday meeting three separate deals that the Elan board has pushed instead of the Royalty takeover bid.

Earlier this month, New York-based Royalty offered to pay $13 per share for each Elan share plus up to $2.50 per share in payments based on performance milestones. That totaled about $7.76 billion not counting the milestone payments.

An Irish Takeover Panel requires Royalty to withdraw its offer if shareholders approved the buyback or the acquisitions. Royalty is challenging that requirement in court.

Royalty Pharma said Monday that Elan shareholders can continue to accept its latest bid while the court challenge is pending. The Irish High Court will hold a hearing Wednesday on the case.

Elan was attempting to diversify its business through the string of acquisitions after it sold its interest in the multiple sclerosis treatment Tysabri to former development partner Biogen Idec Inc. earlier this year. That deal was worth $3.25 billion in cash and recurring royalty payments.

The acquisitions included purchasing a share of the royalties for four drugs from Theravance Inc., as well as acquiring Austrian drug developer AOP Orphan. Elan said last week it would explore selling the company after it became clear that shareholders would reject the acquisitions.

Elan also said Royalty could participate in its formal sale process, but it urged shareholders to steer clear of Royalty's latest bid.

Royalty is a privately held company that buys drug royalty interests. It has made several bids this year to buy Elan.

U.S.-traded shares of Elan fell 10 cents to $13.56 Monday in midday trading, while the Standard & Poor's 500 index climbed about 1 percent.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Judge halts Royalty Pharma's bid for Elan stock

Jun 04, 2013

Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the ...

Recommended for you

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.